Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Acceleron, Shire Ink Collaboration
by Rick Mullin
September 20, 2010
| A version of this story appeared in
Volume 88, Issue 38
Acceleron Pharma and Shire have formed a joint development and commercialization agreement under which Shire will obtain rights outside the U.S. to a range of Acceleron molecules targeting activin receptor type IIB pathway, which helps regulate skeletal muscle growth. The collaboration will initially investigate ACE-031, currently in Phase II clinical trials for patients with Duchenne muscular dystrophy (DMD). Shire will make an up-front payment of $45 million to Acceleron, as well as possible milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X